LONDON, Sept. 10, 2019 /PRNewswire/ -- Smith+Nephew (LSE:
SN, NYSE: SNN), the global medical technology business, is pleased
to announce the US launch of the new PICO 7Y Single Use Negative
Pressure Wound Therapy System (sNPWT) with AIRLOCK™ Technology.
This is the first PICO sNPWT pump to include an innovative
integrated Y connector, enabling the utilization of two dressings
concurrently from one pump, allowing for two wounds or incisions to
be addressed simultaneously. PICO 7Y is appropriate for use on a
variety of wound types such as closed surgical incisions, chronic
and acute wounds.
The PICO 7Y sNPWT kit includes two large multisite dressings
with extended soft port, designed to conform to complex
anatomies.1 It is particularly suited for use on
multiple wounds (for example breast procedures). The PICO 7Y pump
also includes a check dressing indicator, which is intended to
reduce unnecessary dressing changes and waste2,3, and is
also 23% quieter than the first generation PICO,4,5
making it less intrusive for patients.
The PICO sNPWT dressing includes a proprietary AIRLOCK
Technology layer that uniformly and consistently delivers
sufficient NPWT across a surgical incision and the surrounding zone
of injury.6,7 This unique feature is designed to help
reduce the risk of wound complications by reducing post-operative
fluid8,9 and tension*10 around a closed
surgical incision, when compared with standard dressings. The
combination of these actions helps reduce the risk of surgical
wound dehiscence11 and surgical site
infections11, the two most common surgical site
complications. In a recent meta-analysis of 16 studies—comprising
over 2,000 incisions across multiple surgical
specialties—prophylactic use of PICO on closed surgical incisions
significantly reduced surgical site infections by 58%, length of
hospital stay by one half a day and wound dehiscence by 26.4% as
compared to standard of care.12
"PICO 7Y is the latest addition to the PICO family of sNPWT
products, which have revolutionized the use of negative pressure
wound therapy by making a treatment, previously predominantly used
in a hospital inpatient setting, available to a wider range of
outpatients in a cost effective, portable
solution.13,14" said Ryan
Frank, Vice President of US Marketing, Advanced Wound
Management. The ability to treat two wounds simultaneously makes
PICO 7Y ideal for procedures such as breast surgeries. "With breast
surgical procedures becoming more frequent,15
increasingly complex,16,17 and with more women at high
risk of breast cancer choosing to undergo risk-reducing surgery
such as bilateral prophylactic mastectomy,18,19 PICO 7Y
is improving the delivery of therapy for what is currently an unmet
need."
PICO™ sNPWT has a strong evidence base with 103 published papers
of which 21 are published RCTs and 65 are unique clinical
studies.20,21
To learn more about PICO 7Y please see
www.possiblewithpico.com/introduction/pico7y
For detailed product information, including indications for use,
contraindications, precautions and warnings, please consult the
product's applicable Instructions for Use (IFU) prior to use.
* as demonstrated in biomechanical modelling
† Absolute difference of 5% (10 patients); p=0.004.
‡ Reduction in wound breakdown: 24 patients; PICO 4.2%; standard
dressings 16.7%. Number of patients too small to test for
statistical significance.
References
- Data on file. A volunteer trial to assess dressing performance
of Palermo multisite vs Control. OR-DOF/42 2014.
- PICO 7Y lndicator activation test report. Internal Report.
RD.18.074 v1. 2018.
- PICO 7Y Human Factors Summary. Internal Report.
WMP/16/533/UEF/R15.2018.
- Smith & Nephew. 2018. PICO 7Y Device Noise Test Report.
Internal Report RD.18.076 v2.
- Data on File Report – DS/17/701/R. Dec
2017 Acoustic Testing Report: Comparison of PICO™ 7 to PICO
1.6 Devices.
- Smith & Nephew October 2017.
Project Opal PICO 7 System Stability Testing, Initial Time Point.
Internal Report. DS/17/253/R.
- Malmsjö M, Huddleston, E., and Martin, R., .Biological Effects
of a Disposable, Canisterless Negative Pressure Wound Therapy
System. ePlasty. 2014;14.
- Karlakki SL, Hamad AK, Whittall C, et al.Incisional negative
pressure wound therapy dressings (iNPWTd) in routine primary hip
and knee arthroplasties: A randomised controlled trial. Bone Joint
Res. 2016;5(8):328-337.
- Payne C, Edwards D.Application of the Single Use Negative
Pressure Wound Therapy Device ( PICO ) on a Heterogeneous Group of
Surgical and Traumatic Wounds. ePlasty. 2014:152-166.
- Loveluck J, Copeland, T., Hill, J., Hunt, A., and Martin, R.,
.Biomechanical Modeling of the Forces Applied to Closed Incisions
During Single-Use Negative Pressure Wound Therapy. ePlasty.
2016.
- Smith & Nephew. April 2019.
Outcomes following PICO compared to conventional dressings when
used prophylactically on closed surgical incisions: systematic
literature review and meta-analysis. Report reference
EO/AWM/PICO/004/v3
- Strugala, V., Martin, R. Meta-analysis of comparative trials
evaluating a prophylactic single-use negative pressure wound
therapy system for the prevention of surgical site complications.
Surgical Infections, Vol. 18, No. 00, 2017.
- Hurd, T. Evaluating the costs and benefits of innovations in
chronic wound care products and practices. Ostomy Wound
Management. 2013; Supplement(June):1–16. Available at:
https://www.o-wm.com/pdf/SN-supp-june.pdf. Accessed 24 September 2018.
- Smith & Nephew. March 2018.
Kendal PICO 7Y - pump weight and dimensions. Internal Report.
DS.18.066.R.
- International Society of Aesthetic Plastic Surgery. ISAPS
statistics infographic for 2016. Available at:
https://www.isaps.org/wp-content/uploads/2017/10/GlobalStatistics.Infographic2016-1.pdf.
Accessed 29 May 2018.
- Dietz J, Lundgren P, Veeramani A, et al. Autologous inferior
dermal sling (autoderm) with concomitant skin-envelope reduction
mastectomy: an excellent surgical choice for women with macromastia
and clinically significant ptosis. Ann Surg Oncol.
2012;19:3282-3288.
- McCulley SJ and Macmillan RD. Planning and use of therapeutic
mammoplasty – Nottingham approach.
Br J Plast Surg 2005;58:889-901.
- Wong SM, Freedman RA, Sagara Y, Aydogan F, Barry WT, Golshan M.
Growing use of contralateral prophylactic mastectomy despite no
improvement in long-term survival for invasive breast cancer.
Ann Surg. 2017;265:581–589.
- Holt R and Murphy J. PICOÔ incision closure in oncoplastic
breast surgery: a case series. Br J Hosp Med 2015;76:217-223.
- Smith & Nephew. Analysis by Dr Vicki Strugala. January
2019.
- Kirsner R, Dove C, Reyzelman A, Vayser D, Jaimes H. A
Prospective, Randomized, Controlled Clinical Trial on the Efficacy
of a Single‐use Negative Pressure Wound Therapy System, Compared to
Traditional Negative Pressure Wound Therapy in the Treatment of
Chronic Ulcers of the Lower Extremities. Wound Rep Regen.
2019. [Epub ahead of print]
About Smith+Nephew
Smith+Nephew is a portfolio medical
technology business that exists to restore people's bodies and
their self-belief by using technology to take the limits off
living. We call this purpose 'Life Unlimited'. Our 16,000+
employees deliver this mission every day, making a difference to
patients' lives through the excellence of our product
portfolio, and the invention and application of new technologies
across our three global franchises of Orthopaedics, Advanced
Wound Management and Sports Medicine & ENT. Founded in
Hull, UK, in 1856, we now operate
in more than 100 countries, and generated annual sales of
$4.9 billion in 2018. Smith+Nephew is
a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group'
and 'Smith+Nephew' are used to refer to Smith & Nephew
plc and its consolidated subsidiaries, unless the context
requires otherwise.
For more information about Smith+Nephew, please
visit www.smith-nephew.com and follow us
on Twitter, LinkedIn, Instagram or Facebook.
To learn more about what we do to help reduce surgical site
complications, please visit www.closertozero.com
Forward-looking Statements
This document may
contain forward-looking statements that may or may not prove
accurate. For example, statements regarding expected revenue growth
and trading margins, market trends and our product pipeline are
forward-looking statements. Phrases such as "aim", "plan",
"intend", "anticipate", "well-placed", "believe", "estimate",
"expect", "target", "consider" and similar expressions are
generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith+Nephew, these factors include: economic
and financial conditions in the markets we serve, especially those
affecting health care providers, payers and customers; price levels
for established and innovative medical devices; developments in
medical technology; regulatory approvals, reimbursement decisions
or other government actions; product defects or recalls or other
problems with quality management systems or failure to comply with
related regulations; litigation relating to patent or other claims;
legal compliance risks and related investigative, remedial or
enforcement actions; disruption to our supply chain or operations
or those of our suppliers; competition for qualified personnel;
strategic actions, including acquisitions and dispositions, our
success in performing due diligence, valuing and integrating
acquired businesses; disruption that may result from transactions
or other changes we make in our business plans or organisation to
adapt to market developments; and numerous other matters that
affect us or our markets, including those of a political, economic,
business, competitive or reputational nature. Please refer to the
documents that Smith+Nephew has filed with the U.S. Securities and
Exchange Commission under the U.S. Securities Exchange Act of 1934,
as amended, including Smith+Nephew's most recent annual report on
Form 20-F, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith+Nephew as of the date of the statement. All written or oral
forward-looking statements attributable to Smith+Nephew are
qualified by this caution. Smith+Nephew does not undertake any
obligation to update or revise any forward-looking statement to
reflect any change in circumstances or in Smith+Nephew's
expectations.
™ Trademark of Smith+Nephew. Certain marks
registered US Patent and Trademark Office.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/smithnephew-launches-pico-7y-in-the-us-a-portable-single-use-negative-pressure-wound-therapy-system-to-treat-two-wounds-simultaneously-300915168.html
SOURCE Smith & Nephew